{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:34:38Z","timestamp":1791488078499,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["631"],"award-info":[{"award-number":["631"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["39129"],"award-info":[{"award-number":["39129"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI25038"],"award-info":[{"award-number":["AI25038"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.04.067","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T19:28:15Z","timestamp":1462130895000},"page":"2779-2786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis"],"prefix":"10.1016","volume":"34","author":[{"given":"Malcolm S.","family":"Duthie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Favila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley A.","family":"Hofmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeung L.","family":"Tutterrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Laurance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Picone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Guderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Remy","family":"Bailor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarthy C.","family":"Vallur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raodoh","family":"Mohamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.04.067_bib0165","series-title":"Control of the Leishmanises. In: WHO Technical Report Series","author":"WHO","year":"2010"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.067_bib0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pt.2015.09.004","article-title":"Best practices for preventing vector-borne diseases in dogs and humans","volume":"32","author":"Dantas-Torres","year":"2015","journal-title":"Trends Parasitol"},{"issue":"7310","key":"10.1016\/j.vaccine.2016.04.067_bib0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","article-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial","volume":"323","author":"Sundar","year":"2001","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.067_bib0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4269\/ajtmh.2002.66.143","article-title":"Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study","volume":"66","author":"Sundar","year":"2002","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.067_bib0185","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin Infect Dis: Off Publ Infect DisSoc Am"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.067_bib0190","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S1473-3099(10)70320-0","article-title":"Visceral leishmaniasis: elimination with existing interventions","volume":"11","author":"Matlashewski","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2016.04.067_bib0195","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.3390\/ijerph7124267","article-title":"Antimony toxicity","volume":"7","author":"Sundar","year":"2010","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"10.1016\/j.vaccine.2016.04.067_bib0200","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.067_bib0205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trstmh.2010.10.008","article-title":"Ambisome plus miltefosine for Indian patients with kala-azar","volume":"105","author":"Sundar","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.067_bib0210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/S1413-86702001000400008","article-title":"Successful use of a defined antigen\/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: a case report","volume":"5","author":"Badaro","year":"2001","journal-title":"Braz J Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2016.04.067_bib0215","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1016\/j.vaccine.2009.05.084","article-title":"Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis","volume":"27","author":"Noazin","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.067_bib0220","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0738-081X(96)00040-5","article-title":"Vaccine for prophylaxis and immunotherapy, Brazil","volume":"14","author":"Genaro","year":"1996","journal-title":"Clin Dermatol"},{"issue":"29\u201330","key":"10.1016\/j.vaccine.2016.04.067_bib0225","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2004.03.058","article-title":"Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran","volume":"22","author":"Mohebali","year":"2004","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.067_bib0230","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s40475-014-0024-9","article-title":"The emergence of defined subunit vaccines for the prevention of Leishmaniasis","volume":"1","author":"Duthie","year":"2014","journal-title":"Curr Trop Med Rep"},{"issue":"15","key":"10.1016\/j.vaccine.2016.04.067_bib0235","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.vaccine.2013.02.025","volume":"31","author":"Guha","year":"2013","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2016.04.067_bib0240","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1086\/430348","article-title":"A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis","volume":"191","author":"Tewary","year":"2005","journal-title":"J Infect Dis"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2016.04.067_bib0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"issue":"202","key":"10.1016\/j.vaccine.2016.04.067_bib0250","doi-asserted-by":"crossref","first-page":"202ra121","DOI":"10.1126\/scitranslmed.3006406","article-title":"Vaccination with leishmania hemoglobin receptor-encoding DNA protects against visceral leishmaniasis","volume":"5","author":"Guha","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.067_bib0255","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2016.04.067_bib0260","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2016.04.067_bib0265","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/iai.63.10.4105-4114.1995","article-title":"Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans","volume":"63","author":"Skeiky","year":"1995","journal-title":"Infect Immun"},{"issue":"14","key":"10.1016\/j.vaccine.2016.04.067_bib0270","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.vaccine.2005.12.027","article-title":"Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB\/c mice against a virulent challenge with Leishmania major","volume":"24","author":"Chenik","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.067_bib0275","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijpara.2012.02.013","article-title":"A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis","volume":"42","author":"Gupta","year":"2012","journal-title":"Int J Parasitol"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.067_bib0280","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4049\/jimmunol.166.1.498","article-title":"Identification and characterization of T cell-stimulating antigens from Leishmania by CD4T cell expression cloning","volume":"166","author":"Probst","year":"2001","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.067_bib0285","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/14760584.2014.894467","article-title":"Identifying vaccine targets for anti-leishmanial vaccine development","volume":"13","author":"Sundar","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.04.067_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis: a review","volume":"422","author":"Jain","year":"2015","journal-title":"J Immunol Methods"},{"issue":"4","key":"10.1016\/j.vaccine.2016.04.067_bib0295","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.067_bib0300","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.det.2015.03.018","article-title":"New world and old world Leishmania infections: a practical review","volume":"33","author":"Kevric","year":"2015","journal-title":"Dermatol Clin"},{"issue":"7","key":"10.1016\/j.vaccine.2016.04.067_bib0305","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"issue":"42","key":"10.1016\/j.vaccine.2016.04.067_bib0310","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1016\/j.vaccine.2007.08.001","article-title":"Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant","volume":"25","author":"Goto","year":"2007","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2016.04.067_bib0315","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.vaccine.2009.02.079","article-title":"Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection","volume":"27","author":"Goto","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.067_bib0320","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/IAI.73.2.812-819.2005","article-title":"Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis","volume":"73","author":"Aguilar-Be","year":"2005","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16302328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16302328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T11:03:17Z","timestamp":1717239797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16302328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":32,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16302328"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}